MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS, NICE TA681, MARCH 2021

RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
BARICITINIB tablets (Olumiant®▼)	**Immunosuppressant; selective and reversible JAK inhibitor**	**Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy; rheumatoid arthritis**	**Final**	**NICE TA681 – recommended**

MSEMOC recommendation:

Baricitinib is recommended as an option option for treating moderate to severe atopic dermatitis in adults, in accordance with NICE technology appraisal recommendations.

NICE TA681 recommendation:

1.1 Baricitinib is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:

- the disease has not responded to at least 1 systemic immunosuppressant, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are not suitable, and
- the company provides it according to the commercial arrangement.

1.2 Assess response from 8 weeks and stop baricitinib if there has not been an adequate response at 16 weeks, defined as a reduction of at least:

- 50% in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
- 4 points in the Dermatology Life Quality Index (DLQI) from when treatment started.

1.3 When using the EASI, take into account skin colour and how this could affect the EASI score, and make appropriate clinical adjustments.

1.4 When using the DLQI, take into account any physical, psychological, sensory or learning disabilities, or communication difficulties that could affect the responses to the DLQI, and make any appropriate adjustments.

1.5 These recommendations are not intended to affect treatment with baricitinib that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

For further information refer to the Summary of Product Characteristics for baricitinib.
Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis: https://www.nice.org.uk/guidance/ta681
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC; MSE Joint Committee
Date Approved	May 2021
Review Date	May 2026 or sooner if subject to any new updates nationally